GLIPIZIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H27N5O4S
Molecular Weight	445.535
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

InChIKey=ZJJXGWJIGJFDTL-UHFFFAOYSA-N

InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)

HIDE SMILES / InChI

Molecular Formula	C21H27N5O4S
Molecular Weight	445.535
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01067
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/glipizide.html

Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide. Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Glipizide is used as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. Glipizide is marketed by Pfizer under the brand name Glucotrol in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams. Other companies also market glipizide, most commonly extended release tablets of 5 and 10 milligrams.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor gamma 109 Target ID: CHEMBL235 Sources: http://www.drugbank.ca/drugs/DB01067	Agonist 2662
Sulfonylurea receptor 1 5 Target ID: CHEMBL2071 Sources: http://www.drugbank.ca/drugs/DB01067	Inhibitor 8228

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 256 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017783s026lbl.pdf	Primary		Approved 8360	GLUCOTROL Approved Use GLUCOTROL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date 4.52735992E11

C_max

Value	Dose	Co-administered	Analyte	Population
523 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16509763	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		GLIPIZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
465 ng/mL EXPERIMENT https://www.ajol.info/index.php/tjpr/article/viewFile/66555/54281	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		GLIPIZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1897 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16509763	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		GLIPIZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1878 ng × h/mL EXPERIMENT https://www.ajol.info/index.php/tjpr/article/viewFile/66555/54281	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		GLIPIZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.65 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16509763	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		GLIPIZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3 h EXPERIMENT https://www.ajol.info/index.php/tjpr/article/viewFile/66555/54281	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		GLIPIZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.5% DRUG LABEL https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/1af56e54-3db7-4b15-bf65-dfaf0eacb515/spl-doc?hl=glipizide			GLIPIZIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
375 mg single, oral Overdose Dose: 375 mg Route: oral Route: single Dose: 375 mg Co-administed with:: melformin, p.o(14.5 g; single) Sources: https://pubmed.ncbi.nlm.nih.gov/16794105 Page: p.565	healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16794105 Page: p.565	Disc. AE: Hypoglycaemia... AEs leading to discontinuation/dose reduction: Hypoglycaemia Sources: https://pubmed.ncbi.nlm.nih.gov/16794105 Page: p.565
1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: insulin, i.v(1600 u; single) Sources: https://pubmed.ncbi.nlm.nih.gov/16909651 Page: p.265	unhealthy, 55 n = 1 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16909651 Page: p.265	Disc. AE: Hypoglycaemic encephalopathy... AEs leading to discontinuation/dose reduction: Hypoglycaemic encephalopathy (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/16909651 Page: p.265
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: melformin, p.o(>/=1500 mg/day; 52 wk) Sources: https://pubmed.ncbi.nlm.nih.gov/17300595 Page: p.199	unhealthy, 56.6 (9.8) n = 584 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 56.6 (9.8) Sex: M+F Population Size: 584 Sources: https://pubmed.ncbi.nlm.nih.gov/17300595 Page: p.199	Disc. AE: Myocardial infarction, Abortion spontaneous... AEs leading to discontinuation/dose reduction: Myocardial infarction (serious, 0.17%) Abortion spontaneous (serious, 0.17%) Sources: https://pubmed.ncbi.nlm.nih.gov/17300595 Page: p.199
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: melformin, p.o(1500–2500mg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/21816980 Page: p.2020	unhealthy, >/=18 years n = 408 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: >/=18 years Sex: M+F Population Size: 408 Sources: https://pubmed.ncbi.nlm.nih.gov/21816980 Page: p.2020	Disc. AE: Hypoglycemia, Pyelonephritis... AEs leading to discontinuation/dose reduction: Hypoglycemia (0.7%) Pyelonephritis (0.25%) Sources: https://pubmed.ncbi.nlm.nih.gov/21816980 Page: p.2020
40 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf Page: p.3	Disc. AE: Cardiovascular disorder NOS... AEs leading to discontinuation/dose reduction: Cardiovascular disorder NOS (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf Page: p.3

AEs

AE	Significance	Dose	Population
Hypoglycaemia	Disc. AE	375 mg single, oral Overdose Dose: 375 mg Route: oral Route: single Dose: 375 mg Co-administed with:: melformin, p.o(14.5 g; single) Sources: https://pubmed.ncbi.nlm.nih.gov/16794105 Page: p.565	healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16794105 Page: p.565
Hypoglycaemic encephalopathy	grade 5 Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: insulin, i.v(1600 u; single) Sources: https://pubmed.ncbi.nlm.nih.gov/16909651 Page: p.265	unhealthy, 55 n = 1 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16909651 Page: p.265
Abortion spontaneous	serious, 0.17% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: melformin, p.o(>/=1500 mg/day; 52 wk) Sources: https://pubmed.ncbi.nlm.nih.gov/17300595 Page: p.199	unhealthy, 56.6 (9.8) n = 584 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 56.6 (9.8) Sex: M+F Population Size: 584 Sources: https://pubmed.ncbi.nlm.nih.gov/17300595 Page: p.199
Myocardial infarction	serious, 0.17% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: melformin, p.o(>/=1500 mg/day; 52 wk) Sources: https://pubmed.ncbi.nlm.nih.gov/17300595 Page: p.199	unhealthy, 56.6 (9.8) n = 584 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 56.6 (9.8) Sex: M+F Population Size: 584 Sources: https://pubmed.ncbi.nlm.nih.gov/17300595 Page: p.199
Pyelonephritis	0.25% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: melformin, p.o(1500–2500mg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/21816980 Page: p.2020	unhealthy, >/=18 years n = 408 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: >/=18 years Sex: M+F Population Size: 408 Sources: https://pubmed.ncbi.nlm.nih.gov/21816980 Page: p.2020
Hypoglycemia	0.7% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: melformin, p.o(1500–2500mg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/21816980 Page: p.2020	unhealthy, >/=18 years n = 408 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: >/=18 years Sex: M+F Population Size: 408 Sources: https://pubmed.ncbi.nlm.nih.gov/21816980 Page: p.2020
Cardiovascular disorder NOS	grade 5 Disc. AE	40 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf Page: p.3

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	substrate 1010

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C19 985

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2C19 985	substrate 3326 Sources: https://link.springer.com/article/10.1007/s00228-009-0736-2	yes		no (pharmacogenomic study) Comment: there were detectable differences between CYP2C19 EMs and PMs in the pharmacokinetics and pharmacodynamics of glipizide, but none of these differences were statistically significant Sources: https://link.springer.com/article/10.1007/s00228-009-0736-2
CYP2C9 1010	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16372821/; https://link.springer.com/article/10.1007/s00228-009-0736-2	yes		weak (co-administration study) Comment: rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01); pharmacogenomic studies also performed: CYP2C9 polymorphism significantly influences the pharmacokinetics and pharmacodynamics of glipizide, which needs to be considered in clinical practice Sources: https://pubmed.ncbi.nlm.nih.gov/16372821/; https://link.springer.com/article/10.1007/s00228-009-0736-2

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5384	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5384
ChemicalBook	CB9185001	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9185001
MolPort	MolPort-002-885-830	https://www.molport.com/shop/molecule-link/MolPort-002-885-830
Selleck Chemicals	Glipizide(Glucotrol)	http://www.selleckchem.com/products/Glipizide(Glucotrol).html
ZINC	ZINC000000537795	http://zinc15.docking.org/substances/ZINC000000537795
eMolecules	27520373	https://www.emolecules.com/cgi-bin/more?vid=27520373
eMolecules	496510	https://www.emolecules.com/cgi-bin/more?vid=496510

PubMed

Title	Date	PubMed
Transdermal delivery of glibenclamide and glipizide: in vitro permeation studies through mouse skin.	2002 Dec	12561248
Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.	2002 Dec	12453952
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.	2002 Dec 15	12517365
Metaglip and Avandamet for type 2 diabetes.	2002 Dec 23	12500153
Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note.	2003	14621971
Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents.	2003	12931039
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.	2003	12859222
[Oral antidiabetic therapy and cardiovascular complications: theoretical problem or clinical evidence?].	2003 Apr 6	12795025
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease.	2003 Aug	12925002
K(ATP) channels and pancreatic islet blood flow in anesthetized rats: increased blood flow induced by potassium channel openers.	2003 Aug	12882921
Effect of some penetration enhancers on the permeation of glibenclamide and glipizide through mouse skin.	2003 Dec	14703968
Hypoglycemic activity of Urtica pilulifera in streptozotocin-diabetic rats.	2003 Feb	12648821
Differential effects of K(ATP) channel blockers on [(3)H]-noradrenaline overflow after short- and long-term exposure to (+)-oxaprotiline or desipramine.	2003 Feb	12595958
Kappa-opioid receptor stimulation contributes to aortic artery dilation through activation of K(ATP) channel in the rats.	2003 Feb 25	12598942
Blinding controlled-release tablets for clinical trials.	2003 Jan	12602488
Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure.	2003 Jan	12602474
Diabetes medicine update. Old dogs, new tricks.	2003 Jan-Feb	12632553
Performance liquid chromatographic analysis of glipizide: application to in vitro and in vivo studies.	2003 Jul	12935300
Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure.	2003 Jul	12719973
Combination agents for diabetes.	2003 Jun	12807051
Insulin secretagogues, but not glucose, stimulate an increase in [Ca2+]i in the fetal human and porcine beta-cell.	2003 Jun	12788884
Small amounts of some drugs can be toxic to young children: one pill or one swallow can require aggressive treatment.	2003 Jun	12776089
Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.	2003 Jun	12766122
Treatment of feline diabetes mellitus using an alpha-glucosidase inhibitor and a low-carbohydrate diet.	2003 Jun	12765629
Modification of cardiovascular response of posterior hypothalamic adenosine A(2) receptor stimulation by adenylate cylase, guanylate cyclase and by K(ATP) channel blockade in anesthetized rats.	2003 Jun 19	12781921
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.	2003 Mar	12852706
Barriers to self-monitoring of blood glucose among adults with diabetes in an HMO: a cross sectional study.	2003 Mar 19	12659642
[Differences between oral antidiabetics].	2003 Mar 20	12693123
Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure.	2003 May	12765455
Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.	2003 May	12759885
Light and scanning electron microscopic evaluation of Glyde File Prep in smear layer removal.	2003 May	12752647
Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.	2003 May-Jun	14613469
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis.	2003 Nov	14693302
Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.	2003 Nov	14602757
Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.	2003 Nov	14565810
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.	2003 Oct	14614647
Managing hemorrhagic shock: fluids on the way out--drugs on the way in?	2003 Oct	14530766
Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats.	2003 Oct	14530747
Weight uniformity of split tablets required by a Veterans Affairs policy.	2003 Sep-Oct	14613437
The role of sulphonylureas in the management of type 2 diabetes mellitus.	2004	15200348
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.	2004	15099124
Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.	2004 Apr	15045685
Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing.	2004 Aug	15373844
Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview.	2004 Dec	15561903
Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.	2004 Feb	14600250
Idiosyncratic toxicity associated with potentiated sulfonamides in the dog.	2004 Jun	15189298
Basal nitric oxide production contributes to membrane potential and vasotone regulation of guinea pig in vitro spiral modiolar artery.	2004 Mar	14987756
Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry.	2004 Mar 5	14751795
Metformin-associated respiratory alkalosis.	2004 May-Jun	15133541
Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry.	2004 Nov 5	15458724

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 5 mg orally once a day, 30 minutes before breakfast Maintenance dose: Up to 40 mg in divided doses 30 minutes before a meal of adequate caloric content. Doses may be increased in intervals of 2.5 to 5 mg a day according to blood glucose response. Maximum single dose: 15 mg Maximum daily dose: 40 mg

Route of Administration: Oral

In Vitro Use Guide

Glipizide (100 uM) increased PPARγ transcriptional activity in Cos7 cells

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:53:19 UTC 2023` Edited by `admin` on `Wed Jul 05 22:53:19 UTC 2023`
Record UNII	X7WDT95N5C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GLIPIZIDE

Official Name

English

1-CYCLOHEXYL-3-((P-(2-(5-METHYLPYRAZINECARBOXAMIDO)ETHYL)PHENYL)SULFONYL)UREA

Common Name

English

GLIPIZIDE [USP MONOGRAPH]

Common Name

English

GLIPIZIDE [JAN]

Common Name

English

GLIPIZIDE COMPONENT OF METAGLIP

Common Name

English

GLIPIZIDE [USAN]

Common Name

English

METAGLIP COMPONENT GLIPIZIDE

Common Name

English

GLIPIZIDE [VANDF]

Common Name

English

K-4024

Code

English

K 4024

Code

English

GLIPIZIDE [USP-RS]

Common Name

English

GLUCOTROL

Brand Name

English

CP-28720

Code

English

GLIPIZIDE SLOW RELEASE

Common Name

English

GLIPIZIDE [EP MONOGRAPH]

Common Name

English

GLIPIZIDE [MART.]

Common Name

English

Glipizide [WHO-DD]

Common Name

English

glipizide [INN]

Common Name

English

GLIPIZIDE [ORANGE BOOK]

Common Name

English

PYRAZINECARBOXAMIDE, N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-5-METHYL-

Systematic Name

English

GLIPIZIDE [MI]

Common Name

English

NSC-759120

Code

English

CP-28,720

Code

English

Classification Tree Code System Code

LIVERTOX

460